CSRC terminates the registration process of Feipeng Biotech.

On February 22, according to the China Securities Regulatory Commission (CSRC), during the process of reviewing the initial public offering (IPO) application of Jinyu Bio-Technology Co., Ltd. (Jinyu Bio-Tech) and its listing on the ChiNext board, both Jinyu Bio-Tech and its sponsor Huatai United Securities Co., Ltd. voluntarily requested to withdraw their registration application files. The CSRC decided to terminate the IPO registration process of Jinyu Bio-Tech. Jinyu Bio-Tech intended to list on the ChiNext board of the Shenzhen Stock Exchange, with Huatai United Securities as the IPO sponsor, aiming to raise 2.5056 billion yuan. The prospectus shows that Jinyu Bio-Tech is a leading supplier of in vitro diagnostic solutions, specializing in the research, development, production, and sales of core raw materials for in vitro diagnostic reagents, as well as providing customers with in vitro diagnostic instruments and reagent solutions. The company has now covered the majority of in vitro diagnostic industrial customers nationwide, including domestic listed companies in the in vitro diagnostics industry such as Shenzhen Mindray Bio-Medical Electronics, BGI Genomics, Sansure Biotech Inc., ShenZhen New Industries Biomedical Engineering, Autobio Diagnostics, Maccura Biotechnology, Beijing Wantai Biological Pharmacy Enterprise, Guangzhou Wondfo Biotech, Zhejiang Orient Gene Biotech, Beijing Strong Biotechnologies, Inc., Dian Diagnostics Group, etc., and has established continuous and good cooperative relationships with them.